These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34129685)

  • 41. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population.
    Lalan S; Abdel-Rahman S; Gaedigk A; Leeder JS; Warady BA; Dai H; Blowey D
    Pediatr Nephrol; 2014 Oct; 29(10):2039-49. PubMed ID: 24875272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients.
    Li JL; Liu S; Fu Q; Zhang Y; Wang XD; Liu XM; Liu LS; Wang CX; Huang M
    Pharmacogenomics; 2015; 16(12):1355-65. PubMed ID: 26228923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients.
    Adie SK; Bitar A; Konerman MC; Dorsch MP; Andrews CA; Pogue K; Park JM
    Pharmacotherapy; 2022 Feb; 42(2):106-111. PubMed ID: 34882822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
    Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
    Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients.
    Riva N; Woillard JB; Distefano M; Moragas M; Dip M; Halac E; Cáceres Guido P; Licciardone N; Mangano A; Bosaleh A; de Davila MT; Schaiquevich P; Imventarza O
    Liver Transpl; 2019 Sep; 25(9):1397-1407. PubMed ID: 31102573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Tacrolimus Intra-Patient Variability during 6-12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers.
    Nuchjumroon A; Vadcharavivad S; Singhan W; Poosoonthornsri M; Chancharoenthana W; Udomkarnjananun S; Townamchai N; Avihingsanon Y; Praditpornsilpa K; Eiam-Ong S
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients.
    Htun YY; Swe HK; Saw TM
    Transplant Proc; 2018 May; 50(4):1034-1040. PubMed ID: 29731062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
    Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
    Liu S; Chen RX; Li J; Zhang Y; Wang XD; Fu Q; Chen LY; Liu XM; Huang HB; Huang M; Wang CX; Li JL
    Acta Pharmacol Sin; 2016 Sep; 37(9):1251-8. PubMed ID: 27498776
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
    Singh R; Srivastava A; Kapoor R; K Sharma R; D Mittal R
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
    Buendia JA; Bramuglia G; Staatz CE
    Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.
    de Jonge H; de Loor H; Verbeke K; Vanrenterghem Y; Kuypers DR
    Pharmacogenomics; 2013 Sep; 14(12):1467-80. PubMed ID: 24024898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients.
    Everton JBF; Patrício FJB; Faria MS; Ferreira TCA; Romao EA; Silva GEB; Magalhães M
    Eur J Clin Pharmacol; 2021 Jun; 77(6):879-886. PubMed ID: 33398393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.
    Flahault A; Anglicheau D; Loriot MA; Thervet E; Pallet N
    Pharmacogenomics; 2017 Jan; 18(2):165-173. PubMed ID: 27977332
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.